Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma
The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies.
San Diego United States Noord Holland Venclexta Venclyxto Mariana Cota Stirner International Myeloma Working Group
Source: onclive.com